Surgical Volume, Safety, Drug Administration, and Clinical Trials During COVID-19: Single-center Experience in Shanghai, China
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Since December 2019, COVID-19 has spread rapidly around the world [1,2]. Patients with genitourological cancers are facing delays to treatment and thus oncological outcomes may be compromised. Here we report the impact of COVID-19 on surgical volumes, surgical safety, drug administration, and clinical trials in our center, which is one of the largest genitourinary cancer departments in China
European Urology , résumé, 2019